Nivolumab Induces Durable Remission in Relapsed/Refractory ALK‐Negative ALCL After Allogeneic Blood Stem Cell Transplantation—A Case Report and Literature Review

Documenti analoghi

• Early Free Light‐Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA‐Directed CAR‐T Cells
  di: Tim Richardson, et al.
  Pubblicazione: (2025)
• Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
  di: Mohammad Shahzaib Qadir, et al.
  Pubblicazione: (2026)
• Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era
  di: Enver Aydilek, et al.
  Pubblicazione: (2026)
• Adenovirus‐Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation
  di: Toru Miyajima, et al.
  Pubblicazione: (2026)
• Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type
  di: Li Yuan Chan, et al.
  Pubblicazione: (2025)